Atlantic Health System | Oncology Research

Research site
100 Madison Avenue, Morristown, New York, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


20 of 62
Status: Active
Trial type: Interventional
Funder type: Industry

7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

This is a Phase 4, U.S. only, multi-center study using a 7-day therapeutic response dose (TRD) of commercial Sucraid® to assess the response of treat...

Congenital Sucrase-Isomaltase Deficiency
Biological: Sucraid (sacrosidase) Oral Solution 8500 IU/mL

This Phase 3, multinational, single-arm, multicenter study will evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patie...

Active, not recruiting
Bladder Cancer
Urothelial Carcinoma
Drug: UGN-102

The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with an...

Melanoma (Skin)
Advanced Solid Tumor
Drug: Ipilimumab
Drug: ANV419

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in particip...

Active, not recruiting
Biological: Ipilimumab
Other: Placebo

The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and...

Solid Tumors
Drug: Nivolumab
Drug: DF6002

The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker pat...

Carcinoma, Non-Small-Cell Lung
Adenocarcinoma of Lung
Drug: Pemetrexed
Drug: Carboplatin

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of th...

Crohn's Disease
Drug: Mirikizumab

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: CC-486
Drug: Venetoclax

The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, G...

Solid Tumor
Epithelial Ovarian Cancer
Drug: Gemcitabine
Drug: Cisplatin

This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in...

Active, not recruiting
Advanced Cancer
Drug: Botensilimab
Drug: AGEN2373

This is a prospective, multi-center, randomized, controlled, patient- and evaluator-blinded study comparing treatment with the CardiAMP cell therapy...

Active, not recruiting
Heart Failure, Systolic
Other: Sham
Biological: Autologous cell therapy

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-H...

Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Drug: Cyclophosphamide
Genetic: CB-010

INDP-D101 is a Phase 1, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of De...

Solid Tumor, Adult
Drug: Decoy20

The objective of the study is to assess the safety and effectiveness of MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes...

Type 2 Diabetes Treated With Insulin
Device: MiniMed™ 780G Insulin Pump system

An open label, dose escalation and dose expansion study to evaluate the safety, tolerability, and anti-tumor activity of STP707 with IV administratio...

Active, not recruiting
Solid Tumor
Drug: STP707

The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus tre...

Active, not recruiting
Tuberous Sclerosis Complex
Drug: everolimus

Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin...

Active, not recruiting
Metastatic Melanoma
Biological: Lifileucel

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects...

Microsatellite Instability
Mismatch Repair Deficiency
Biological: RP1
Biological: nivolumab

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for teliso...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

Keynote 695 is Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients w...

Active, not recruiting
Stage III/IV Melanoma
Biological: Pembrolizumab
Biological: tavokinogene telseplasmid

Trial conditions

Melanoma (9 trials)
Prolapse (7 trials)
Cancer (6 trials)
Pelvic Organ Prolapse (6 trials)
Carcinoma (5 trials)
Adenocarcinoma (4 trials)
COVID-19 (4 trials)
Urinary Incontinence (4 trials)
Leukemia (3 trials)
Non-Small-Cell Lung Carc... (3 trials)

And 67 more

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems